CAS 114078-88-5

5-bromotriazine

Description:

5-Bromotriazine is a heterocyclic organic compound characterized by a triazine ring structure with a bromine substituent at the 5-position. This compound typically exhibits a pale yellow to white crystalline appearance and is known for its stability under standard conditions. The presence of the bromine atom enhances its reactivity, making it useful in various chemical applications, including as a building block in the synthesis of agrochemicals and pharmaceuticals. 5-Bromotriazine is also notable for its potential as a reagent in organic synthesis, particularly in reactions involving nucleophilic substitution. Its solubility can vary depending on the solvent, but it generally shows moderate solubility in polar organic solvents. Additionally, the compound's properties, such as melting point and boiling point, are influenced by the bromine substituent, which can affect its intermolecular interactions. Safety precautions should be taken when handling this compound, as it may pose health risks if inhaled or ingested, and proper storage conditions should be maintained to ensure stability.

Formula: C₃H₂BrN₃

InChI: InChI=1/C3H2BrN3/c4-3-1-5-7-6-2-3/h1-2H

SMILES: c1c(cnnn1)Br

Synonyms:

• 1,2,3-Triazine, 5-Bromo-
• 5-Bromo-1,2,3-triazine
• 5-bromotriazine

1,2,3-Triazine, 5-bromo-

CAS: 114078-88-5

Formula: C₃H₂BrN₃

Purity: 95%

Color and Shape: Solid

Molecular weight: 159.9721

Ref: IN-DA000AIF

5-Bromo-1,2,3-triazine

CAS: 114078-88-5

5-Bromo-1,2,3-triazine

Purity: 95%

Molecular weight: 159.97g/mol

Ref: 54-OR84141

5-Bromo-1,2,3-triazine

CAS: 114078-88-5

Formula: C₃H₂BrN₃

Purity: 95%

Molecular weight: 159.974

Ref: 10-F431084

5-Bromo-1,2,3-triazine

CAS: 114078-88-5

Etoricoxib is a nonsteroidal anti-inflammatory drug that is marketed for the relief of osteoarthritis and rheumatoid arthritis. Etoricoxib is an inhibitor of cyclooxygenase-2, which is involved in the inflammatory response. It also inhibits the activity of lipoxygenases, which are enzymes that oxidize fatty acids to form leukotrienes. Etoricoxib has been found to be a potent inhibitor of cytochrome P450 (CYP) 2C9, CYP2C19, CYP2D6 and CYP3A4. Etoricoxib was also found to bind to DNA in calf thymus tissue with high affinity. This binding may inhibit transcription or replication.

Formula: C₃H₂BrN₃

Purity: Min. 95%

Molecular weight: 159.97 g/mol

Ref: 3D-PEA07888